MISBA
Live / Applied — Response to non-final action entered (as of 12 Sept 2026)
What this means for you
Not registered yet, but its 26 Nov 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79440214
- Mark type
- Stylized text
- Filed
- 26 Nov 2025
- Attorney of record
- Rebecca Liebowitz
Goods and services
- Class 001 — Chemicals: Chemicals for scientific purposes; chemicals for use in research; chemicals, enzymes, and biological preparations in the nature of DNA and RNA for research use; chemicals for use in the preparation and creation of DNA and RNA; enzymes for use in the preparation and creation of DNA and RNA; molecular biology research tools in the nature of biological, chemical and biochemical reagents for research use
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment and prevention of ophthalmological conditions, hearing loss, hematologic diseases, immune response disorders, autoimmune conditions and disorders, neurological disorders, neurodegenerative disorders, psychiatric disorders, respiratory diseases, fibrosis, hepatic diseases, renal diseases, diseases of the pancreas, metabolic diseases, genetic conditions, cancer, infectious diseases and cardiovascular diseases; medical and veterinary preparations for therapeutic purposes, for the treatment and prevention of ophthalmological conditions, hearing loss, hematologic diseases, immune response disorders, autoimmune conditions and disorders, neurological disorders, neurodegenerative disorders, psychiatric disorders, respiratory diseases, fibrosis, hepatic diseases, renal diseases, diseases of the pancreas, metabolic diseases, genetic conditions, cancer, infectious diseases and cardiovascular diseases; biological, chemical and biochemical reagents for medical use; DNA, RNA, oligonucleotides, and polynucleotides for medical and veterinary use; gene editing enzymes for medical and veterinary use; medical and veterinary preparations containing therapeutic DNA and RNA, for the treatment and prevention of ophthalmological conditions, hearing loss, hematologic diseases, immune response disorders, autoimmune conditions and disorders, neurological disorders, neurodegenerative disorders, psychiatric disorders, respiratory diseases, fibrosis, hepatic diseases, renal diseases, diseases of the pancreas, metabolic diseases, genetic conditions, cancer, infectious diseases and cardiovascular diseases; biological, chemical and biochemical reagents for medical or veterinary use
- Class 042 — Scientific and technological services: Scientific and technological services and research and design relating thereto, namely scientific research services in the field of genomics; medical and veterinary research services, including the manipulation of biological reagents to be used for medical, veterinary or therapeutic purposes; chemical and biological analysis and research services; medical and scientific research into DNA and RNA; medical and scientific research and product development into regarding the creation of DNA and RNA; medical and scientific research and product development services in the field of the manufacture of synthetic DNA, RNA, genes and oligonucleotides for others; medical and scientific research, product development, product testing and research laboratory analysis services in the field of genomics, DNA and RNA sequencing, gene synthesis, gene identification, gene cloning, gene expression, and gene mapping; scientific and medical research in the fields of molecular biology, next generation sequencing, high-throughput sequencing, and bioinformatics; medical and scientific research in the fields of DNA and RNA modelling services; gene engineering services; medical and scientific research and product development services regarding the creation of genome libraries or collections of biologicals including chemicals and compounds; medical and scientific research and product development services in regarding creating libraries or collections of normal and mutated genes; scientific services relating to the discovery and the preclinical and clinical development of therapeutic products; medical and scientific research consultancy
Owner
Prosecution history
- 12 Sept 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 12 Sept 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 12 Sept 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 04 Jun 2026 — REFUSAL PROCESSED BY IB
- 15 May 2026 — NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
- 14 May 2026 — REFUSAL PROCESSED BY MPU
- 31 Mar 2026 — NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
- 30 Mar 2026 — NON-FINAL ACTION WRITTEN
- 30 Mar 2026 — ASSIGNED TO EXAMINER
- 04 Jan 2026 — APPLICATION FILING RECEIPT MAILED
- 04 Jan 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 25 Dec 2025 — SN ASSIGNED FOR SECT 66A APPL FROM IB